金吾财讯 | 再鼎医药（ZLAB）宣布，其自主研发的新型长效IL-13/IL-31Rα双特异性抗体ZL-1503在全球I/Ib期临床试验的单次递增剂量（SAD）部分中，取得了积极的首次人体试验初步数据。试验结果显示，健康志愿者在接受200毫克至1000毫克剂量的ZL-1503单次给药后，关键特应性皮炎（AD）生物标志物pSTAT6实现了至少90%的快速且近乎完全抑制，且疗效持续长达12周。在药代动力学方面，该药血清半衰期长达40至50天，暴露量与剂量呈正比，这一特性为其未来支持每12周一次的延长维持给药间隔奠定了坚实基础。安全性上，ZL-1503在所有评估剂量下均耐受良好，未报告严重不良事件或抗药抗体。再鼎医药透露，旨在评估该药在中重度特应性皮炎患者中多次递增剂量的B部分试验队列数据预计将于2027年上半年公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.